SCHEMBL2970080

SCHEMBL2970080

O=C(Nc1cc(F)cc(N2CCOCC2)c1)c1ccc(Cl)c(NC(=O)c2ccc(Cl)nc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.65
SMN1; SMN2 Q16637 5/20 0.56
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 2/20 0.55
GAA P10253 1/20 0.55
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPK14 Q16539 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPK13 O15264 1/20 0.50
MAPK12 P53778 1/20 0.50
MAPK11 Q15759 1/20 0.50
PLAU P00749 1/20 0.49
CSF1R P07333 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
HTT P42858 2/20 0.48
HPGD P15428 1/20 0.48
NFKB1 P19838 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5897239 0.91 MAPT (0.66) MAPTSMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL2980968 0.87 KCNQ3 (0.52) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL2979404 0.84 SMN1; SMN2 (0.56) MAPTSMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL2974983 0.84 PLAU (0.47) MAPTSMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL7850678 0.83 MAPT (0.60) MAPTSMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL28741190 0.83 RAB9A (0.51) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL5897317 0.82 MAPK14 (0.66) MAPTMAPK14TDP1CSF1R
SCHEMBL2977919 0.81 PLAU (0.55) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL27545834 0.80 MAPT (0.60) MAPTSMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL2972292 0.80 SMN1; SMN2 (0.52) MAPTSMN1; SMN2KDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 MAPT 4659/4885SMN1; SMN2 4288/4885KDM4E 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.